Brief: Immunovant Q1 Net Income USD -87.15 Million
06/08/2024 21:05
Aug 06 (Reuters) - Immunovant Q1 operating expenses USD 94.281 million. * Q1 basic EPS USD -0.6
Recent news on Immunovant
See all newsU.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies
Immunovant Q3 net loss smaller than expected
Brief: Immunovant Q3 Net Income USD -110.635 Million Vs. IBES Estimate USD -125.1 Million